IMMVF (Immunovia AB) Operating Margin %: -4,945.00% (As of Mar. 2026)


IMMVF Immunovia AB IMMVF
43 GF Score
Price $0.02
GF Value $0.01
! 4 Warning Signs
View Full Analysis

What is Immunovia AB Operating Margin %?

Immunovia AB IMMVF -61.59% 43 Operating Margin % is -4,945.00% as of Mar. 2026. GuruFocus rates IMMVF with a GF Score™ of 43/100 and a GF Value™ of $0.01. The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Immunovia AB ranks worse than 97.54% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Immunovia AB's Operating Income for the three months ended in Mar. 2026 was $-1.98 Mil. Immunovia AB's Revenue for the three months ended in Mar. 2026 was $0.04 Mil. Therefore, Immunovia AB's Operating Margin % for the quarter that ended in Mar. 2026 was -4,945.00%.

Good Sign:

Immunovia AB operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Immunovia AB's Operating Margin % or its related term are showing as below:

IMMVF' s Operating Margin % Range Over the Past 10 Years
Min: -37203.87   Med: -19294.37   Max: -8480.79
Current: -8695.65


IMMVF's Operating Margin % is ranked worse than
97.54% of 203 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.29 vs IMMVF: -8695.65

Immunovia AB's 5-Year Average Operating Margin % Growth Rate was 18.60% per year.

Immunovia AB's Operating Income for the three months ended in Mar. 2026 was $-1.98 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.51 Mil.


Immunovia AB  (OTCPK:IMMVF) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Immunovia AB Operating Margin % Related Terms


Immunovia AB Operating Margin % Historical Data

* Premium members only.

The historical data trend for Immunovia AB's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunovia AB Operating Margin % Chart

Immunovia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19,724.73 -16,749.09 -18,777.27 -11,731.76 -11,698.65

Immunovia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13,328.57 -23,333.33 -24,300.00 -4,636.84 -4,945.00

IMMVF vs TMO, DHR, IDXX: Operating Margin % Comparison

For the Diagnostics & Research subindustry, Immunovia AB's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunovia AB Operating Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Immunovia AB's Operating Margin % falls into.


IMMVF
43GF Score
Immunovia AB IMMVF
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunovia AB Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Immunovia AB's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-8.657 / 0.074
=-11,698.65 %

Immunovia AB's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-1.978 / 0.04
=-4,945.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -4,945.00% mean?
Immunovia AB (IMMVF) has a Operating Margin % of -4,945.00% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Immunovia AB and its competitors. According to the industry distribution chart, Immunovia AB ranks #198 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 97.5%.
Is Immunovia AB's Operating Margin % too high?
Immunovia AB's current Operating Margin % is -4,945.00%. Based on the distribution chart, Immunovia AB ranks #198 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Immunovia AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Operating Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Immunovia AB ranks #198 out of 203 companies for Operating Margin %. This places Immunovia AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Immunovia AB and its competitors. Immunovia AB's current Operating Margin % is -4,945.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Immunovia AB (IMMVF) has a current Operating Margin % of -4,945.00%. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 100% above its estimated fair value. The current Operating Margin % is -4,945.00%. Immunovia AB's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Immunovia AB (IMMVF), the current Operating Margin % is -4,945.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immunovia AB (IMMVF) Overvalued in 2026?

Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued. The current stock price of $0.02 is trading 100% above its estimated GF Value™ of $0.01.

Key valuation signals for IMMVF:

  • Operating Margin %: -4,945.00%
  • GF Value™: $0.01 vs. price of $0.02 (100% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the IMMVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Immunovia AB Business Description

Other Exchanges IMMNOV:Sweden0G8X:UK
Address Scheelevagen 8, Medicon Village, Lund, SWE, 223 63
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
43GF Score

Get the complete analysis for IMMVF

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price
$0.01
GF Value